Particulars (Rupees in Crores.) | Sept-2024 | Mar-2024 | Sept-2023 | Mar-2023 | Sept-2022 |
---|---|---|---|---|---|
Gross Sales | 15,688.8 | 14,297.8 | 13,618.6 | 13,066.8 | 11,521.1 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 15,688.8 | 14,297.8 | 13,618.6 | 13,066.8 | 11,521.1 |
Other Operating Income | 45.5 | 52.8 | 41.9 | 38.2 | 43.6 |
Other Income | 486.7 | 411.5 | 497.5 | 186.6 | 905.9 |
Total Income | 16,221 | 14,762.1 | 14,158 | 13,291.6 | 12,470.6 |
Total Expenditure | 11,507.9 | 10,487.9 | 9,590.1 | 9,608.3 | 8,712.4 |
PBIDT | 4,713.1 | 4,274.2 | 4,567.9 | 3,683.3 | 3,758.2 |
Interest | 135.5 | 98.7 | 72.4 | 77.2 | 65.6 |
PBDT | 4,577.6 | 4,175.5 | 4,495.5 | 3,606.1 | 3,692.6 |
Depreciation | 777.6 | 741.2 | 728.8 | 639.2 | 611 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 1,292.8 | 636.1 | 1,309.8 | 737.5 | 76.9 |
Deferred Tax | -227.1 | 107.5 | -430.3 | 25.3 | 701.5 |
Reported Profit After Tax | 2,734.3 | 2,690.7 | 2,887.2 | 2,204.1 | 2,303.2 |
Minority Interest After NP | 86.2 | 0 | 0 | 0 | 0 |
Net Profit after Minority Interest | 2,648.1 | 2,690.7 | 2,887.2 | 2,204.1 | 2,303.2 |
Extra-ordinary Items | 0 | 0 | 0 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | 2,648.1 | 2,690.7 | 2,887.2 | 2,204.1 | 2,303.2 |
EPS (Unit Curr.) | 159 | 161.31 | 173.64 | 132.3 | 138.77 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 83.4 | 83.4 | 83.4 | 83.3 | 83.2 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 30.04 | 29.89 | 33.54 | 28.18 | 32.62 |
PBDTM(%) | - | - | - | - | - |
PATM(%) | 17.42 | 18.81 | 21.2 | 16.86 | 19.99 |
The company logged a growth of 15.9% in its revenue from operations at ₹8,358.60 Crore versus ₹7,215 Crore in Q3FY24.
Here are some of the stocks that may see significant price movement today: Indus Towers, Dr Reddy’s Laboratories, Mankind Pharma, etc.
Here are some of the stocks that may see significant price movement today: Dr Reddy’s Laboratories, RITES, Canara Bank, etc.
Dr Reddy's already signed a license and commercialisation deal for Toripalimab with Shanghai Junshi Biosciences Co. Ltd in 2023.
Dr Reddy’s Laboratories shares has gained a total of 5.62% in the last one year, and 2.45% since the beginning of the year.
Here are some of the stocks that may see significant price movement today: UPL, Tata Power, JSW Steel, Dr Reddy’s, etc.
EBITDA for the quarter increased 5% year-on-year to ₹2,280 Crore between July and September 2024, while margins improved modestly to 28.4%.
Here are some of the stocks that may see significant price movement today: Dr Reddy’s, Hindustan Zinc, Titan Company, etc.
Here are some of the stocks that may see significant price movement today: Mazagon Dock Shipbuilders, Krsnaa Diagnostics, Dr Reddy's, etc.
The experiment also had a favourable safety profile, with no serious adverse effects such as Cytokine Release Syndrome (CRS) or neurotoxicity reported.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.